NFE2L2 and non-small cell lung carcinoma: On the other hand, the results of an in vitro study of human lung cancer cells (A549/DDP, a cisplatin-resistant A549, and H838 cell lines) demonstrated that treatment with metformin combined with cisplatin produced the dephosphorylation of Nrf2, accelerating its proteasomal degradation and overcoming chemoresistance in NSCLC [118].